

ASHOK SHARMA & ASSOCIATES

CHARTERED ACCOUNTANTS

311, "DEEP SHIKHA",
RAJENDRA PLACE,
NEW DELHI - 110 008
TEL: 25769764

To

The Board of Directors,
Medicamen Biotech Ltd.
10, Community Centre No-2,
Ashok Vihar, Phase-II
Delhi-110052

REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Medicamen Biotech Limited for the period ended 31st December, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ASHOK SHARMA & ASSOCIATES
CHARTERED ACCOUNTANTS



PLACE: NEW DELHI
DATE: 14/02/2015

M. No. : 500805

MEDICAMEN Biotech Limited




Regd. Office :
10, Community Centre No. 2,
Ashok Vihar, Phase-II
Delhi-110052
CIN No. : L74899DL1993PLC056594

Tel. : 27463506, 47589500
Toll Free No. : 1800 3000 7889,
1800 1029 010
Fax : 011-27138171
Web : www.medicamen.com

Provisional Financial Results for the quarter ended 31st December 2014

PART I

Particulars	(Rupees in Lakh)					
	Quarter Ended			Nine Months Ended		Year Ended
	3 Months Ended 31/12/2014	Preceding 3 Months Ended 30/09/2014	Corresponding 3 Months Ended 31/12/2013	9 Monthss Ended 31/12/2014	9 Monthss Ended 31/12/2013	Year Ended 31/03/2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
01. Income						
(a) Net Sales/Income from operations (Net of excise duty)	1289.34	2730.76	1201.80	5922.35	5085.70	7324.86
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
(c) Total Income from Operations (Net)	1289.34	2730.76	1201.80	5922.35	5085.70	7324.86
02. Expenses						
(a) Cost of Material Consumed	850.30	1628.85	714.21	3651.13	2894.42	4444.06
(b) Purchase of Goods Traded	59.07	146.81	86.20	286.64	247.50	349.96
(c) Changes in inventory of Finished Goods & Work-in-Progress	(267.81)	223.57	(44.62)	(9.67)	192.88	148.89
(d) Employees Benefits Expenses	164.16	154.47	138.86	474.58	419.41	557.56
(e) Depreciation & Amortisation Expenses	52.61	53.15	40.43	157.64	121.04	160.94
(f) Other expenses	442.60	408.19	254.50	1223.08	952.49	1416.61
TOTAL EXPENSES	1300.92	2615.04	1189.58	5783.40	4827.74	7078.00
03. Profit/(Loss) from Operations before Other Income, Finance Cost & Exceptional Items (1-2)	(11.57)	115.73	12.22	138.95	257.96	246.86
04. Other Income	34.85	16.38	7.80	95.86	21.62	60.62
05. Profit/(Loss) from ordinary activities before Finance Cost & Exceptional Items (3+4)	23.28	132.11	20.03	234.81	279.58	307.48
06. Finance Cost	65.42	70.95	72.05	199.46	212.10	289.61
07. Profit/(Loss) from ordinary activities after Finance Cost but before Exceptional Items (5-6)	(42.14)	61.15	(52.03)	35.35	67.48	17.87
08. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
09. Profit/(Loss) from Ordinary Activities before tax (7+8)	(42.14)	61.15	(52.03)	35.35	67.48	17.87
10. Tax Expenses						
Current Year	(8.03)	11.65	(9.91)	6.74	12.86	3.41
Tax Related to Earlier Year	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	2.80	(0.54)	0.63	(14.86)	0.82	5.05
11. Net Profit/(Loss) from Ordinary Activities After Tax (9-10)	(36.91)	50.04	(42.74)	43.48	53.80	9.42
12. Extraordinary Items (Net of Tax expenses)	-	-	-	-	-	-
13. Net Profit/(Loss) for the period (11-12)	(36.91)	50.04	(42.74)	43.48	53.80	9.42
14. Paid-up equity share capital (Rs. 10/- per share)	891.36	891.36	849.00	891.36	849.00	891.36
15. Reserve excluding revaluation reserves						736.40
16. Earning Per Share before & after Extra Ordinary Items (Rs.) (not annualised)						
Basic	(0.41)	0.56	(0.50)	0.49	0.63	0.11
Diluted	(0.41)	0.56	(0.50)	0.49	0.63	0.11



PART II

Select Information for the Quarter ended 31st December, 2014

Particulars	3 Months Ended 31/12/2014	Preceding 3 Months Ended 30/09/2014	Corresponding 3 Months Ended 31/12/2013	9 Monthss Ended 31/12/2014	9 Monthss Ended 31/12/2013	Year Ended 31/03/2014
A. Particulars of Shareholding						
1. Public Shareholding						
- No. of Shares	51,43,518	51,43,518	51,74,591	51,43,518	51,74,591	51,43,518
- Percentage of Shareholding holding	57.70	57.70	60.95	57.70	60.95	57.70
2. Promoters & Promoter Group Shareholding						
a) Pledged/Encumbered						
- Number of Shares	18,61,200	18,61,200	18,16,200	18,61,200	18,61,200	18,61,200
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	49.37	49.37	56.14	49.37	56.14	49.37
- Percentage of Shares (as a % of the total share capital of the company)	20.88	20.88	21.92	20.88	21.92	20.88
b) Non-encumbered						
- Number of Shares	19,08,888	19,08,888	14,54,209	19,08,888	14,54,209	19,08,888
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	50.63	50.63	43.86	50.63	43.86	50.63
- Percentage of Shares (as a % of the total share capital of the company)	21.41	21.41	17.13	21.41	17.13	21.42

B. Investor Complaints	3 Months ended 31/12/2014
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaning unresolved at the end of the quarter	Nil

NOTES :

1. The above results after being reviewed by the Audit Committee were taken on record by the Board at its Meeting held on 14th February, 2015
2. Limited Review as required under Clause 41 of Listing Agreement has been carried out by the statutory auditors.
3. The figures are regrouped in previous year also, wherever considered necessary.
4. The company operates in single segment, viz. Pharmaceutical Formulations.
5. Depreciation for the period April to December, 2014, has been calculated as per the provisions of the Companies Act, 2013 and the amount of Depreciation during the Quarter ended December 2014 is more by Rs. 12.72 as compared to Quarter ended Dec 2013. In addition to depreciation charged for the curen period, an amount of Rs.47.34 Lacs has been recognised in the opening reserves, for assets whose useful life is NIL.

For & on behalf of Board of Directors
Medicamen Biotech Limited

(Signature)
DELHI-52
INDIA

(B.K.Gupta)
Managing Director

Place : Delhi
Dated : 14.02.2015